ATE534902T1 - Replikationsproteinn ciz1 - Google Patents

Replikationsproteinn ciz1

Info

Publication number
ATE534902T1
ATE534902T1 AT03782605T AT03782605T ATE534902T1 AT E534902 T1 ATE534902 T1 AT E534902T1 AT 03782605 T AT03782605 T AT 03782605T AT 03782605 T AT03782605 T AT 03782605T AT E534902 T1 ATE534902 T1 AT E534902T1
Authority
AT
Austria
Prior art keywords
replication protein
ciz1
modulate
activity
relates
Prior art date
Application number
AT03782605T
Other languages
English (en)
Inventor
Coverley Dawn
Original Assignee
Cizzle Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cizzle Biotechnology Ltd filed Critical Cizzle Biotechnology Ltd
Application granted granted Critical
Publication of ATE534902T1 publication Critical patent/ATE534902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03782605T 2002-12-05 2003-12-05 Replikationsproteinn ciz1 ATE534902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228337.2A GB0228337D0 (en) 2002-12-05 2002-12-05 Replication protein
PCT/GB2003/005334 WO2004051269A2 (en) 2002-12-05 2003-12-05 Ciz1 replication protein

Publications (1)

Publication Number Publication Date
ATE534902T1 true ATE534902T1 (de) 2011-12-15

Family

ID=9949091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03782605T ATE534902T1 (de) 2002-12-05 2003-12-05 Replikationsproteinn ciz1

Country Status (12)

Country Link
US (3) US7833702B2 (de)
EP (2) EP2316966B1 (de)
JP (1) JP2006508659A (de)
CN (1) CN1720442A (de)
AT (1) ATE534902T1 (de)
AU (1) AU2003290240B2 (de)
CA (1) CA2507403C (de)
ES (2) ES2556704T3 (de)
GB (1) GB0228337D0 (de)
HU (1) HUE028241T2 (de)
MX (1) MXPA05006034A (de)
WO (1) WO2004051269A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
JP2009159869A (ja) * 2007-12-28 2009-07-23 Univ Of Occupational & Environmental Health Japan 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
GB0901837D0 (en) * 2009-02-05 2009-03-11 Cizzle Biotechnology Ltd Cancer diagnosis and treatment
JP5952815B2 (ja) * 2010-08-04 2016-07-13 シズル バイオテクノロジー リミテッド ガンの診断および処置のための方法および化合物
CN103421886B (zh) * 2012-05-21 2018-10-12 上海吉凯基因化学技术有限公司 Ciz1基因的用途及其相关药物
WO2017057567A1 (ja) * 2015-10-02 2017-04-06 株式会社村田製作所 電力増幅モジュール、フロントエンド回路および通信装置
GB201518466D0 (en) 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
WO2017126615A1 (ja) * 2016-01-19 2017-07-27 国立大学法人 東京大学 経時変化の情報を基に細胞を回収する方法およびシステム
CN109694411A (zh) * 2017-10-21 2019-04-30 蔡胜和 抗-ciz1抗体
WO2019079914A1 (zh) * 2017-10-23 2019-05-02 蔡胜和 抗-ciz1抗体
CN108796083B (zh) * 2018-06-25 2021-03-19 山东大学 Ciz1作为诊治舌体血管瘤的分子标记物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
EP1242443A4 (de) * 1999-12-23 2005-06-22 Nuvelo Inc Neue nukleinsäuren und polypeptide
AU2001243642A1 (en) * 2000-03-13 2001-10-08 Incyte Genomics, Inc. Transcription factors
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
NL2003837C2 (en) * 2008-11-19 2010-08-05 Rijk Zwaan Zaadteelt En Zaadhandel Bv Resistance to post harvest deterioration in cucumber.

Also Published As

Publication number Publication date
US7833702B2 (en) 2010-11-16
WO2004051269A2 (en) 2004-06-17
ES2556704T3 (es) 2016-01-19
CA2507403C (en) 2015-01-20
US9541555B2 (en) 2017-01-10
AU2003290240B2 (en) 2012-06-14
EP1570268B1 (de) 2011-11-23
JP2006508659A (ja) 2006-03-16
HUE028241T2 (en) 2016-12-28
AU2003290240A1 (en) 2004-06-23
MXPA05006034A (es) 2006-01-27
GB0228337D0 (en) 2003-01-08
US20110070591A1 (en) 2011-03-24
US20060155113A1 (en) 2006-07-13
EP2316966B1 (de) 2015-09-16
CN1720442A (zh) 2006-01-11
EP2316966A1 (de) 2011-05-04
WO2004051269A3 (en) 2004-10-28
CA2507403A1 (en) 2004-06-17
US20160011200A1 (en) 2016-01-14
ES2376746T3 (es) 2012-03-16
EP1570268A2 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
WO2005100998A3 (de) Membrane markers for use in cancer diagnosis and therapie
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP1629084A4 (de) Modulation der expression von c-reaktivem protein
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
DK1587957T3 (da) Genekspressionsmarkør til prognose af brystkræft
ATE534902T1 (de) Replikationsproteinn ciz1
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
WO2006048291A3 (en) Transcriptome microarray technology and methods of using the same
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
DE60235408D1 (de) Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
TW200724679A (en) Treatment of disease using an improved regulated expression system
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
ATE291738T1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide